Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

Neurology

Volumn 47, Issue 4, 1996, Pages 895-900

  Andersen, O ^a   Lycke, J ^a,c   Tollesson, P O ^a   Svenningsson, A ^a   Runmarker, B ^a   Linde, A S ^b   Astrom M ^b   Gjorstrup P ^b   Ekholm, S ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Pharmacia Oncology Immunology   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; PLACEBO; QUINOLINE DERIVATIVE; ROQUINIMEX;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOMODULATION; MALE; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; MYALGIA; PERICARDITIS; PHASE 2 CLINICAL TRIAL; PLEURISY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SKIN TOXICITY; TREATMENT OUTCOME;

EID: 0029838040     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.4.895     Document Type: Article

References (27)

1. Khoury SJ, Weiner HL. Therapy of multiple sclerosis, with particular reference to recent clinical trials. Curr Opin Neurol Neurosurg 1991;4:191-195.
2. Stålhandske T, Kalland T. Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology 1986;11: 87-92.
3. Larsson E, Joki A, Stålhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int J Immunopharmacol 1987;9:425-431.
4. Tarkowski A, Gunnarsson K, Stålhandske T. Effects of LS 2616 administration upon the autoimmune disease of (NZB × NZW) F1 hybrid mice. Immunology 1986;59:589-594.
5. Karussis D, Lehmann D, Brenner T, et al. Immunomodulation of experimental autoimmune myasthenia gravis with Linomide. J Neuroimmunol 1994;55:187-193.
6. Gross D, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia 1994;37:1195-1201.
7. Ilbäck N, Fohlman J, Slorach S, Friman G. Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackie virus B3 myocarditis. J Immunol 1989;142: 3225-3228.
8. Kleinau S, Larsson P, Björk J, Holmdahl R, Klareskog L. Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clin Exp Immunol 1989;78:138-142.
9. Björk J, Kleinau S. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 1989;27:319-321.
10. Karussis DM, Lehmann D, Slavin S, et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide. Ann Neurol 1993;34:654-660.
11. Karussis D, Lehmann D, Slavin S, et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993;90:6400-6404.
12. Karussis DM, Meiner Z, Lehmann D, Gomori J-M, Schwarz A, Linde A, Abramsky O. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996;47: 341-346.
13. Poser CM, Paty DW, Scheinberg L, et al. In: Poser CM, Paty DW, Scheinberg L, McDonald WI, Ebers GC, eds. The diagnosis of multiple sclerosis. Stuttgart: Georg Thieme, 1984;225-229.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
15. Miller D, Barkhof F, Berry I, Kappos L, Scotti G, Thompson A. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
16. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. J Neurol 1996; 243:214-224.
17. Tibbling G, Link H, Öhman S. Principles of albumin and IgG analyses in neurological disorders. Scand J Clin Lab Invest 1977;37:385-390.
18. Svenningsson A, Andersen O, Edsbagge M, Stemme S. Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid. J Neuroimmunol 1995;63:39-46.
19. Gruber R, Reiter C, Riethmuller G. Triple immunofluorescence flow cytometry, using whole blood, of CD4+ and CD8+ lymphocytes expressing CD45RO and CD45RA. J Immunol Methods 1993;163:173-179.
20. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
21. Khoury SJ, Guttmann CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: Correlation between disability and lesion burden. Neurology 1994;44:2120-2124.
22. Miller D, Barkhof F, Nauta J. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
23. Kermode A, Tofts P, Thompson A, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40:229-235.
24. Thompson A, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
25. Gonzalo J, Gonzalez-García A, Kalland T, Hedlund G, Martinez C, Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993;23:2372-2374.
26. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991;34:159-164.
27. Riekmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.